Boston Scientific's (BSX) CHAMPION-AF trial of its heart implant device to lower stroke risk is among the most anticipated study readouts this year, Oppenheimer said in a note Thursday.

"To be clear, consensus view is that the trial will be successful, both technically & clinically," the report said.

The clinical trial is evaluating left atrial appendage closure versus non-vitamin K antagonist oral anticoagulants in a broad non-valvular atrial fibrillation patient population to establish Watchman FLX as a first-line stroke risk-reduction therapy.

The report said how the trial data stacks up will be critical in expanding the total addressable market.

"In our view, the data has to withstand the "clinical success" criteria for true TAM expansion," the report said.

Oppenheimer has an outperform rating with a $100 price target.

Price: 70.55, Change: +0.77, Percent Change: +1.10